French Medtechs Demand Attention To Ongoing Reimbursement Delays
French medtech manufacturers are expecting positive results from recent ministerial efforts to make the national health-care products reimbursement agency, the CEPS, speed up its current slow handling of applications for products and services to enter commercial use in France's public-health system.
You may also be interested in...
Eric Le Roy, chief executive of the French medical technology industry association SNITEM, is angry about the national reimbursement authority's failure to get to grips with staffing shortages holding up price-setting for new technologies, and its current preoccupation with medtech pricing cuts. "Enough is enough," he said in an interview.
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.
For many, the EU MDR is coming too fast, yet several of its crucial elements are not yet in place. Germany’s liberal FDP MPs say the national government needs to make a stand and address a European issue that will impact German patients. In a motion to parliament, the MPs propose fast-tracking for innovative products and measures to keep orphan devices in circulation.